The US FDA Approves Hugel’s Letybo for the Treatment of Glabellar Lines
Shots:
- The US FDA has granted approval to the company’s Letybo for 50 and 100 units to treat moderate-to-severe glabellar lines in adults
- The approval was based on the data from three P-III completed studies that recruited more than 1,000 participants across the US and the EU
- The data from the clinical studies showed the effectiveness and favorable safety profile of Letybo as a treatment for glabellar lines
Ref: PR Newswire | Image: Allergan
Related News:- Allergan and AbbVie Report the Results for TrenibotulinumtoxinE (BoNT/E) In P-III Trials for the Treatment of Glabellar Lines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
